Asunaprevir (BMS-650032) for the treatment of hepatitis C virus

被引：6

作者：

Akamatsu, Nobuhisa ^{[1
]}

Sugawara, Yasuhiko ^{[2
,3
]}

Kokudo, Norihiro ^{[1
]}

机构：

[1] Univ Tokyo, Dept Surg, Artificial Organ & Transplantat Surg Div, Bunkyo Ku, Tokyo 1138655, Japan

[2] Japanese Red Cross Med Ctr, Div Hepatobiliary Pancreat Surg, Shibuya Ku, 4-1-22 Hiroo, Tokyo 1508935, Japan

[3] Japanese Red Cross Med Ctr, Div Liver transplantat, Shibuya Ku, Tokyo 1508935, Japan

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 11期

关键词：

asunaprevir; daclatasvir; direct-acting antiviral; hepatitis C virus; interferon-free treatment; liver transplantation; sustained virologic response; HCV GENOTYPE 1; SUSTAINED VIROLOGICAL RESPONSE; NS3 PROTEASE INHIBITOR; DACLATASVIR PLUS ASUNAPREVIR; PEGYLATED INTERFERON-ALPHA; TREATMENT-NAIVE PATIENTS; ACTING ANTIVIRAL AGENTS; SOFOSBUVIR PLUS; PEGINTERFERON ALPHA; RESISTANCE ANALYSIS;

D O I：

10.1586/14787210.2015.1091724

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Asunaprevir, a second-generation NS3 protease inhibitor of hepatitis C virus (HCV), exhibits strong antiviral activity against HCV genotypes 1 and 4, but relatively weak activity against genotypes 2 and 3. For chronic HCV infection, asunaprevir with daclatasvir as an interferon-free dual treatment achieves a sustained virologic response of nearly 90% in genotype 1b, and a triple regimen with beclabuvir achieves an sustained virologic response > 90%. Asunaprevir and daclatasvir dual treatment can be safely and effectively administered to liver transplant recipients with recurrent HCV. The major drawback of asunaprevir is its low threshold to resistance, which can be overcome by combining it with other direct-acting antivirals. Further studies of asunaprevir in combination with other direct-acting antivirals for the treatment of patients with HCV genotypes 1 or 4 and renal impairment or end-stage renal disease under hemodialysis, HIV-coinfection and liver and/or kidney transplant recipients are warranted.

引用

页码：1307 / 1317

页数：11

共 77 条

[1] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[2] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Reddy, K. Rajender ;

Nelson, David R. ;

Lawitz, Eric ;

Gordon, Stuart C. ;

Schiff, Eugene ;

Nahass, Ronald ;

Ghalib, Reem ;

Gitlin, Norman ;

Herring, Robert ;

Lalezari, Jacob ;

Younes, Ziad H. ;

Pockros, Paul J. ;

Di Bisceglie, Adrian M. ;

Arora, Sanjeev ;

Subramanian, G. Mani ;

Zhu, Yanni ;

Dvory-Sobol, Hadas ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

Kwo, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493

[3] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[4] Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C [J].

Bronowicki, Jean-Pierre ;

Ratziu, Vlad ;

Gadano, Adrian ;

Thuluvath, Paul J. ;

Bessone, Fernando ;

Martorell, Claudia T. ;

Pol, Stanislas ;

Terg, Ruben ;

Younes, Ziad ;

He, Bing ;

Eley, Timothy ;

Cohen, David ;

Yu, Fei ;

Hernandez, Dennis ;

McPhee, Fiona ;

Mendez, Patricia ;

Hughes, Eric .

JOURNAL OF HEPATOLOGY, 2014, 61 (06) :1220-1227

[5] Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C [J].

Bronowicki, Jean-Pierre ;

Pol, Stanislas ;

Thuluvath, Paul J. ;

Larrey, Dominique ;

Martorell, Claudia T. ;

Rustgi, Vinod K. ;

Morris, David W. ;

Younes, Ziad ;

Fried, Michael W. ;

Bourliere, Marc ;

Hezode, Christophe ;

Reddy, K. Rajender ;

Massoud, Omar ;

Abrams, Gary A. ;

Ratziu, Vlad ;

He, Bing ;

Eley, Timothy ;

Ahmad, Alaa ;

Cohen, David ;

Hindes, Robert ;

McPhee, Fiona ;

Reilly, Bridget ;

Mendez, Patricia ;

Hughes, Eric .

ANTIVIRAL THERAPY, 2013, 18 (07) :885-893

[6] Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis:: A retrospective study [J].

Bruno, Savino ;

Stroffolini, Tommaso ;

Colombo, Massimo ;

Bollani, Simona ;

Benvegnu, Luisa ;

Mazzella, Giuseppe ;

Ascione, Antonio ;

Santantonio, Teresa ;

Piccinino, Felice ;

Andreone, Pietro ;

Mangia, Alessandra ;

Gaeta, Giovanni B. ;

Persico, Marcello ;

Fagiuoli, Stefano ;

Almasio, Piero L. .

HEPATOLOGY, 2007, 45 (03) :579-587

[7] Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease [J].

Charlton, Michael ;

Everson, Gregory T. ;

Flamm, Steven L. ;

Kumar, Princy ;

Landis, Charles ;

Brown, Robert S., Jr. ;

Fried, Michael W. ;

Terrault, Norah A. ;

O'Leary, Jacqueline G. ;

Vargas, Hugo E. ;

Kuo, Alexander ;

Schiff, Eugene ;

Sulkowski, Mark S. ;

Gilroy, Richard ;

Watt, Kymberly D. ;

Brown, Kimberly ;

Kwo, Paul ;

Pungpapong, Surakit ;

Korenblat, Kevin M. ;

Muir, Andrew J. ;

Teperman, Lewis ;

Fontana, Robert J. ;

Denning, Jill ;

Arterburn, Sarah ;

Dvory-Sobol, Hadas ;

Brandt-Sarif, Theo ;

Pang, Phillip S. ;

McHutchison, John G. ;

Reddy, K. Rajender ;

Afdhal, Nezam .

GASTROENTEROLOGY, 2015, 149 (03) :649-659

[8] Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors [J].

Coppola, Nicola ;

Pisaturo, Mariantonietta ;

Sagnelli, Caterina ;

Sagnelli, Evangelista ;

Angelillo, Italo F. .

PLOS ONE, 2014, 9 (04)

[9] A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations [J].

Dickinson, Bryan C. ;

Packer, Michael S. ;

Badran, Ahmed H. ;

Liu, David R. .

NATURE COMMUNICATIONS, 2014, 5

[10] Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease [J].

Eley, T. ;

Han, Y-H ;

Huang, S-P ;

He, B. ;

Li, W. ;

Bedford, W. ;

Stonier, M. ;

Gardiner, D. ;

Sims, K. ;

Rodrigues, A. D. ;

Bertz, R. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (02) :159-166

← 1 2 3 4 5 6 7 8 →